Radiation for ETMR: Literature review and case series of patients treated with proton therapy
- PMID: 30582019
- PMCID: PMC6297264
- DOI: 10.1016/j.ctro.2018.11.002
Radiation for ETMR: Literature review and case series of patients treated with proton therapy
Abstract
Background and purpose: Embryonal tumors with multilayered rosettes (ETMRs) are aggressive tumors that typically occur in young children. Radiation is often deferred or delayed for these patients due to late effects; proton therapy may mitigate some of these concerns. This study reviews the role of radiation in ETMR and describes initial results with proton therapy.
Materials and methods: Records of patients with embryonal tumor with abundant neuropil and true rosettes (ETANTR), medulloepithelioma (MEP), and ependymoblastoma (EPL) treated with proton therapy at our institution were retrospectively reviewed. A literature review of cases of CNS ETANTR, MEP, and EPL published since 1990 was also conducted.
Results: Seven patients were treated with proton therapy. Their median age at diagnosis was 33 months (range 10-57 months) and their median age at radiation start was 42 months (range 17-58 months). Their median overall survival (OS) was 16 months (range 8-64 months), with three patients surviving 36 months or longer. Five patients had disease progression prior to starting radiation; all 5 of these patients failed in the tumor bed. A search of the literature identified 204 cases of ETMR with a median OS of 10 months (range 0.03-161 months). Median OS of 18 long-term survivors (≥36 months) in the literature was 77 months (range 37-184 months). Of these 18 long-term survivors, 17 (94%) received radiotherapy as part of their initial treatment; 14 of them were treated with craniospinal irradiation.
Conclusions: Outcomes of patients with ETMR treated with proton therapy are encouraging compared to historical results. Further study of this rare tumor is warranted to better define the role of radiotherapy.
Keywords: ETANTR; ETMR; Ependymoblastoma; Medulloepithelioma; Pediatric; Proton; Radiation.
Similar articles
-
LIN28A, a sensitive immunohistochemical marker for Embryonal Tumor with Multilayered Rosettes (ETMR), is also positive in a subset of Atypical Teratoid/Rhabdoid Tumor (AT/RT).Childs Nerv Syst. 2017 Nov;33(11):1953-1959. doi: 10.1007/s00381-017-3551-6. Epub 2017 Jul 25. Childs Nerv Syst. 2017. PMID: 28744687
-
Embryonal tumors with multilayered rosettes: A tertiary care centre experience.Clin Neurol Neurosurg. 2021 Mar;202:106508. doi: 10.1016/j.clineuro.2021.106508. Epub 2021 Jan 27. Clin Neurol Neurosurg. 2021. PMID: 33556852 Review.
-
Clinicopathological characteristics and outcomes in embryonal tumor with multilayered rosettes: A decade long experience from a tertiary care centre in North India.Ann Diagn Pathol. 2021 Aug;53:151745. doi: 10.1016/j.anndiagpath.2021.151745. Epub 2021 Apr 19. Ann Diagn Pathol. 2021. PMID: 33964610
-
Embryonal tumor with multilayered rosettes of the fourth ventricle: case report.J Neurosurg Pediatr. 2015 Nov;16(5):579-583. doi: 10.3171/2015.3.PEDS1525. Epub 2015 Aug 7. J Neurosurg Pediatr. 2015. PMID: 26252622
-
Extracranial extra-CNS spread of embryonal tumor with multilayered rosettes (ETMR): case series and systematic review.Childs Nerv Syst. 2018 Apr;34(4):649-654. doi: 10.1007/s00381-017-3657-x. Epub 2017 Nov 25. Childs Nerv Syst. 2018. PMID: 29177676
Cited by
-
Genetic mutation and immune infiltration in embryonal tumor with multilayered rosettes.Childs Nerv Syst. 2024 Sep;40(9):2685-2696. doi: 10.1007/s00381-024-06461-1. Epub 2024 May 28. Childs Nerv Syst. 2024. PMID: 38802706
-
ETMR: a tumor entity in its infancy.Acta Neuropathol. 2020 Sep;140(3):249-266. doi: 10.1007/s00401-020-02182-2. Epub 2020 Jun 29. Acta Neuropathol. 2020. PMID: 32601913 Free PMC article. Review.
-
Ependymoblastoma with pulmonary metastasis in an adolescent: A case report.Front Neurol. 2022 Aug 9;13:964856. doi: 10.3389/fneur.2022.964856. eCollection 2022. Front Neurol. 2022. PMID: 36016544 Free PMC article.
-
Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers.Neuro Oncol. 2021 Nov 2;23(23 Suppl 5):S4-S15. doi: 10.1093/neuonc/noab183. Neuro Oncol. 2021. PMID: 34725698 Free PMC article. Review.
-
A modified IRS-III chemotherapy regimen leads to prolonged survival in children with embryonal tumor with multilayer rosettes.Neurooncol Adv. 2020 Sep 18;2(1):vdaa120. doi: 10.1093/noajnl/vdaa120. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 33196040 Free PMC article.
References
-
- Eberhart C.G., Brat D.J., Cohen K.J., Burger P.C. Pediatric neuroblastic brain tumors containing abundant neuropil and true rosettes. Pediatr Dev Pathol. 2000;3:346–352. - PubMed
-
- Korshunov A., Remke M., Gessi M., Ryzhova M., Hielscher T., Witt H. Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol. 2010;120:253–260. - PubMed
-
- Pfister S., Remke M., Castoldi M., Bai A.H.C., Muckenthaler M.U., Kulozik A. Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. Acta Neuropathol. 2009;117:457–464. - PubMed
LinkOut - more resources
Full Text Sources